Business
Lunai Bioworks and BrainStorm Therapeutics launch foundation-funded Parkinson's and rare epilepsy AI collaboration
Lunai Bioworks and BrainStorm Therapeutics have launched a foundation-funded neurology collaboration pairing AI-driven target discovery with human brain...
CSPC receives AZ's USD 1.2b upfront from long-acting peptide collaboration
AstraZeneca has confirmed receipt of a USD 1.2 billion upfront payment by CSPC Pharmaceutical Group (HKEX: 1093) under a strategic collaboration and license...
Ratio Therapeutics expands PharmaLogic manufacturing collaboration for Ac-225RTX-2358 alpha therapy
Ratio Therapeutics has expanded its manufacturing collaboration with radiopharmaceutical CDMO PharmaLogic Holdings Corp. to scale clinical supply of...
Pfizer licenses USD 650m upfront Innovent oncology portfolio in USD 10.5b deal
Pfizer has committed USD 650 million upfront to license a portfolio of 12 early-stage oncology programs from Innovent Biologics (HKEX: 01801), in a deal...
Reprogram Biosciences closes USD 6m seed round for intratumoral mRNA reprogramming platform
Reprogram Biosciences, a preclinical oncology company based in San Carlos, California, has closed a seed financing round that brings total capital raised to...
Apogee secures USD 1.3b from Blackstone for zumilokibart Phase III advancement
San Francisco-based Apogee Therapeutics (Nasdaq: APGE) has announced a strategic financing collaboration with funds managed by Blackstone Life Sciences,...
Bonito Bio and DaltonTx collaborate on agentic AI for CNS-targeted oligotherapeutics delivery
Bonito Biosciences and DaltonTx are combining large-scale ligand screening with agentic AI to tackle one of the most persistent bottlenecks in RNA medicine:...
LifeArc backs Elpida Therapeutics AAV gene therapy programs for three ultra-rare childhood diseases
LifeArc backs Elpida Therapeutics gene therapy push for three ultra-rare childhood diseases
Asahi Kasei licenses ADC bioconjugation platform from The Noguchi Institute
Asahi Kasei Life Science, a subsidiary of Asahi Kasei Corporation (TSE: 3407; OTC: AHKSY), has licensed a glycan-based antibody-drug conjugate...
Q32 Bio raises USD 55m in private placement as bempikibart enters Phase II for alopecia
Waltham, Massachusetts-based Q32 Bio Inc. (Nasdaq: QTTB) announced a USD 55 million private placement of common stock and pre-funded warrants to fund the...
Qyuns picks up milestone from Roche as TSLP/IL-33 BsAb enters clinic
Roche has received the first clinical milestone under its global exclusive licensing agreement with Qyuns Therapeutics (HKEX: 2509), triggered by the dosing...
XtalPi receives USD 19m second payment from DoveTree under USD 5.89b AI drug discovery deal
XtalPi Holdings (HKEX: 2228) has received a second payment of USD 19 million from DoveTree under their AI-driven drug discovery collaboration, bringing...
Protuoso Bio backed with USD 9.5m seed funding for fusion protein platform
San Carlos-based Protuoso Biosciences announced the close of an oversubscribed USD 9.5 million seed financing round to advance its MUXBODY fusion protein...
Editas prices USD 319m offering as EDIT-401 gene therapy for hyperlipidemia progresses
Cambridge, Massachusetts-based Editas Medicine (Nasdaq: EDIT) has announced the pricing of an underwritten public offering of common stock and accompanying...
Assembly follows Gilead option exercise with USD 115m share offering
South San Francisco-based Assembly Biosciences (Nasdaq: ASMB) has closed an underwritten registered public offering of common stock and pre-funded warrants,...
The AllSci Brief
Systematic R&D and deal news. Daily.